CLINICAL ASPECTS OF MALIGNANT MESOTHELIOMA IN AUSTRALIA

被引:17
作者
DRISCOLL, TR
BAKER, GJ
DANIELS, S
LEE, J
THOMPSON, R
FERGUSON, DA
LEIGH, J
机构
[1] WORKSAFE AUSTRALIA, NATL INST OCCUPAT HLTH & SAFETY, OCCUPAT MED UNIT, SYDNEY, AUSTRALIA
[2] ROYAL PRINCE ALFRED HOSP, SYDNEY, NSW, AUSTRALIA
[3] UNIV SYDNEY, SYDNEY, NSW 2006, AUSTRALIA
来源
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE | 1993年 / 23卷 / 01期
关键词
MALIGNANT MESOTHELIOMA; CLINICAL; ASBESTOS;
D O I
10.1111/j.1445-5994.1993.tb00532.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Australia is currently experiencing an epidemic of malignant mesothelioma. The clinical aspects of malignant mesothelioma were investigated in 295 Australian patients as part of a national study of the disease. Most patients were male (91%), with the mean age at diagnosis being 64 years. The predominant cell type was epithelial (38%) and the majority of primary tumours arose from the pleura (94%). Mean survival was poor (17.6 months from first symptom; 11.8 months from diagnosis). Patients with a pleural primary tumour were more likely to present with dyspnoea, chest pain and cough; to have a pleural effusion diagnosed radiologically; and to have metastatic spread. Patients with a peritoneal primary tumour were more likely to present with weight loss, loss of appetite, abdominal pain and ascites; to have radiologic evidence of asbestos exposure; and to have spread along a needle track created during a diagnostic tap. A minority of patients had past thoracic conditions, or radiologic findings, specifically related to previous asbestos exposure. About one fifth of patients had no known asbestos exposure. Forty-one per cent of subjects received some form of chemotherapy, radiotherapy and/or surgery, but no formal disease staging had been documented for any patient. Proper controlled trials of secondary and tertiary treatments in malignant mesothelioma are now needed.
引用
收藏
页码:19 / 25
页数:7
相关论文
共 43 条
[1]  
ADAMS VI, 1986, CANCER, V58, P1540, DOI 10.1002/1097-0142(19861001)58:7<1540::AID-CNCR2820580727>3.0.CO
[2]  
2-5
[3]   EPIDEMIOLOGY OF MALIGNANT MESOTHELIOMA IN WESTERN-AUSTRALIA [J].
ARMSTRONG, BK ;
MUSK, AW ;
BAKER, JE ;
HUNT, JM ;
NEWALL, CC ;
HENZELL, HR ;
BLUNSDON, BS ;
CLARKEHUNDLEY, MD ;
WOODWARD, SD ;
HOBBS, MST .
MEDICAL JOURNAL OF AUSTRALIA, 1984, 141 (02) :86-88
[4]  
BAKER G, 1991, AUST NZ J MED, V21, P646
[5]  
BERRY G, 1991, BRIT J IND MED, V48, P793
[6]   PLEURECTOMY FOR MESOTHELIOMA [J].
BRANCATISANO, RP ;
JOSEPH, MG ;
MCCAUGHAN, BC .
MEDICAL JOURNAL OF AUSTRALIA, 1991, 154 (07) :455-&
[7]   PLEUROPNEUMONECTOMY IN MANAGEMENT OF DIFFUSE MALIGNANT MESOTHELIOMA OF PLEURA - EXPERIENCE WITH 29 PATIENTS [J].
BUTCHART, EG ;
ASHCROFT, T ;
BARNSLEY, WC ;
HOLDEN, MP .
THORAX, 1976, 31 (01) :15-24
[8]  
DEKLERK NH, 1989, MED J AUSTRALIA, V151, P616
[9]   MALIGNANT MESOTHELIOMA - THE RISING EPIDEMIC [J].
FERGUSON, D .
MEDICAL JOURNAL OF AUSTRALIA, 1989, 150 (05) :233-235
[10]   THE AUSTRALIAN MESOTHELIOMA SURVEILLANCE PROGRAM 1979-1985 [J].
FERGUSON, DA ;
BERRY, G ;
JELIHOVSKY, T ;
ANDREAS, SB ;
ROGERS, AJ ;
FUNG, SC ;
GRIMWOOD, A ;
THOMPSON, R .
MEDICAL JOURNAL OF AUSTRALIA, 1987, 147 (04) :166-+